**Table S1: Characteristics of patients starting a second and third TNFi**

|  |  |  |
| --- | --- | --- |
|  | **Second TNFi****N=270** | **Third TNFi****N=111** |
| Females (n (%))  |  164 (60.7)  | 76 (68.5) |
| Age (years; mean (SD)) | 47.0 (11.7) | 46.9 (11.2) |
| Disease duration (years; mean (SD)) | 15.1 (9.12) | 16.1 (8.2) |
| TNFi (n (%))    | Etanercept Infliximab Adalimumab Golimumab Certolizumab | 121 (44.8)34 (12.6)113 (41.8)2 (0.7)0 (0) | 21 (18.9)31 (27.9)48 (43.2)10 (9.0)1 (0.1) |
| Year of initiation (n) |  200220032004200520062007200820092010201120122013 | 01543384036312216793 | 0011149111181717112 |

**Figure S1:** Persistence of TNFi by co-medication with MTX



Kaplan-Meier plot of time (years) to discontinuation of treatment by co-medication with Methotrexate, statistical comparison by log-rank test. A. Etanercept; p=0.16, B. Infliximab; p=0.75, C. Adalimumab; p=0.92